行为干预促进类风湿关节炎达标治疗的整群随机试验
本研究在美国风湿科诊所开展整群随机行为干预试验,比较达标治疗与常规诊疗在类风湿关节炎患者中的可行性与疗效。共纳入每臂14个诊所(达标治疗246例、常规诊疗286例),随访12个月。结果显示两组治疗加速率(47% vs 50%)与低疾病活动度达标率(57% vs 55%)均无显著差异,并识别出患者意愿低与用药延迟等障碍。
要点
- 达标治疗组与常规诊疗组的治疗加速率和低疾病活动度达标率均相似。
- 两组治疗加速率:达标治疗47% vs 常规诊疗50%(OR 0.92,95%CI 0.64–1.34)。
- 低疾病活动度达标率:达标治疗57% vs 常规诊疗55%(OR 1.05,95%CI 0.60–1.84)。
核心结论
- 在美国典型风湿科实践中,达标治疗策略未增加治疗加速或低疾病活动度达成的可能性。
- 患者意愿低和用药延迟被报告为治疗加速的常见障碍。
研究设计与样本
- 行为干预整群随机试验,风湿科诊所按整群随机分配至达标治疗或常规诊疗。
- 每臂14个诊所,达标治疗组246例、常规诊疗组286例,入组为中高疾病活动度(CDAI>10)患者,随访12个月。
- 两组患者每3个月随访一次;达标治疗组医生对CDAI>10者应每月随访并至少每3个月加速治疗。
主要发现
- 治疗加速率:达标治疗47% vs 常规诊疗50%(OR 0.92,95%CI 0.64–1.34)。
- 低疾病活动度(CDAI≤10)达标率:达标治疗57% vs 常规诊疗55%(OR 1.05,95%CI 0.60–1.84)。
- 两组基线人口学与临床特征相似。
关键数值与推荐
- 中高疾病活动度定义为CDAI评分>10。
- 低疾病活动度定义为CDAI评分≤10。
- 共同主要终点为可行性(以CDAI>10条件下的治疗加速率评估)和意向性分析下的低疾病活动度达成。
临床怎么用
- 在常规风湿科实践中推行达标治疗需关注患者意愿与用药延迟等障碍。
- 达标治疗流程本身未必提高治疗加速率或低疾病活动度达标率,需配套解决实施障碍。
局限性
- 原文未报告具体局限性内容。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To assess the feasibility and efficacy of implementing a treat-to-target approach versus usual care in a US-based cohort of rheumatoid arthritis patients. METHODS: In this behavioral intervention trial, rheumatology practices were cluster-randomized to provide treat-to-target care or usual care. Eligible patients with moderate/high disease activity (Clinical Disease Activity Index [CDAI] score >10) were followed for 12 months. Both treat-to-target and usual care patients were seen every 3 months. Treat-to-target providers were to have monthly visits with treatment acceleration at a minimum of every 3 months in patients with CDAI score >10; additional visits and treatment acceleration were at the discretion of usual care providers and patients. Coprimary end points were feasibility, assessed by rate of treatment acceleration conditional on CDAI score >10, and achievement of low disease activity (LDA; CDAI score ≤10) by an intent-to-treat analysis. RESULTS: A total of 14 practice sites per study arm were included (246 patients receiving treat-to-target and 286 receiving usual care). The groups had similar baseline demographic and clinical characteristics. Rates of treatment acceleration (treat-to-target 47% versus usual care 50%; odds ratio [OR] 0.92 [95% confidence interval (95% CI) 0.64, 1.34]) and achievement of LDA (treat-to-target 57% versus usual care 55%; OR 1.05 [95% CI 0.60, 1.84]) were similar between groups. Treat-to-target providers reported patient reluctance and medication lag time as common barriers to treatment acceleration. CONCLUSION: This study is the first to examine the feasibility and efficacy of a treat-to-target approach in typical US rheumatology practice. Treat-to-target care was not associated with increased likelihood of treatment acceleration or achievement of LDA, and barriers to treatment acceleration were identified.
引用
- Harrold LR, Reed GW, John A, et al. Cluster-Randomized Trial of a Behavioral Intervention to Incorporate a Treat-to-Target Approach to Care of US Patients With Rheumatoid Arthritis. Arthritis Care Res (Hoboken). 2018. PMID: 28544704. doi:10.1002/acr.23294
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。